Chosa Oncology (CHOSA) Q3 2024 earnings summary

Executive summary

• Achieved significant progress in projects and increased support from key oncology opinion leaders, with growing recognition for cisplatin-DRP technology.

• Strengthened collaborations with global clinical specialists in multiple cancer types, enhancing strategic execution.

• Professor Fred R. Hirsch, a leading oncologist, joined the board, reinforcing scientific leadership.

• Ongoing discussions with potential partners and stakeholders to secure licensing and commercial agreements.

Financial highlights

• Q3 2024 result after financial items: -1,864 TSEK (Q3 2023: -1,151 TSEK); EPS: -0.307 SEK (Q3 2023: -1.05 SEK).

• Nine-month result: -5,291 TSEK (2023: -21,123 TSEK); cash and cash equivalents at 30 Sep 2024: 9,939 TSEK (2023: 1,151 TSEK).

• Equity at 30 Sep 2024: 17,906 TSEK (2023: 19,200 TSEK); total assets: 20,454 TSEK (2023: 22,437 TSEK).

• No operating revenue; main costs relate to administration and support for Danish subsidiaries.

Outlook and guidance

• Confident outlook based on strengthened financial position and ongoing strategic partnerships.

• Focus remains on licensing, sales, or partnerships for LiPlaCis and cisplatin-DRP technologies.